Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales.
The cash payment under the Nektar-AstraZeneca agreement was triggered by the first commercial...
Memory and as well as connections between brain cells were restored in mice with a model of...
AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.
Pharmaceutical companies sponsoring clinical trials showed strong improvement in their relationships with global investigative sites, according a recent survey.
The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu — fragile doses got too warm.
AstraZeneca has announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 (“the ‘834 patent”), protecting PULMICORT RESPULES in the US, is invalid.
The Justice Department says AstraZeneca will pay $7.9 million to settle allegations it engaged in a kickback scheme involving drugs such as heartburn medicines Nexium and Prilosec.
AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic CancersJanuary 29, 2015 1:06 pm | News | Comments
AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.
The study assessed BRILINTA® (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start.
MedImmune Enters Licensing Agreement with Omnis Pharmaceuticals for Oncolytic Viruses in Immuno-OncologyJanuary 12, 2015 8:43 am | News | Comments
This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus program, a genetically engineered strain of vesicular stomatitis virus (VSV).
The FDA granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca. The FDA also approved a companion diagnostic test from Myriad Genetics. The test is to be used to identify women most likely to benefit from the new medication.
AstraZeneca today announced that the European Commission has granted Marketing Authorization for Lynparza™ capsules as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cance.
Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.
Dynavax Technologies and AstraZeneca signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma.
AstraZeneca today announced that the FDA has accepted for filing the NDA for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC).
Eli Lilly and and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
AstraZeneca has announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.
Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals.
AstraZeneca has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding.
AstraZeneca and Amgen today announced that AMAGINE-3TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12
AstraZeneca has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
Isis Pharmaceuticals has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers.
AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration to Evaluate IMBRUVICA In Hematologic CancersNovember 4, 2014 6:09 pm | News | Comments
AstraZeneca and Pharmacyclics announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers.
AstraZeneca today announced that the FDA has approved once-daily XIGDUO™ XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes.
An increase in the number of prescriptions of a powerful antipsychotic drug for conditions not approved by Health Canada is raising concern about what medical experts call lack of professional and government oversight of doctors' prescribing practices.
- Page 1